Hepatic Adenomatosis: A Systematic Review of Definitions, Management, and Outcomes in Published Cases
GE - Portuguese Journal of Gastroenterology · 27.08.2026 · 33 (1) · 606-619
DOI: 10.1159/pjg/acwag002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift GE - Portuguese Journal of Gastroenterology, online erschienen am 27.08.2026. Verfasst von Thomas Stirrat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Residency Program, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Hepatic adenomatosis (HA), the multifocal phenotype of hepatocellular adenoma, is variably defined and managed.
Methods
We performed a PRISMA-guided systematic review of MEDLINE, Embase, Web of Science, and CINAHL from inception through August 25, 2025, and included human case reports or case series with original clinical data.
Results
The review included 54 reports describing 55 patients. Most patients were female (81.8%), with median age of 34 years (IQR 26–48). A ≥10-lesion threshold was used in 68.5% of definitions. When lesion burden was quantifiable, the median lesion count was 15 (IQR 10–30; range 4–200). The median largest-lesion diameter was 80 mm (IQR 50–100; maximum 170 mm), and 80.4% measured ≥5 cm. Magnetic resonance imaging (MRI) was reported in two-thirds of cases, whereas hepatobiliary-phase imaging and molecular subtyping were rarely described. Management included observation, resection, embolization, ablation, and transplantation, most often for size, hemorrhage risk, or malignancy concern; reported follow-up documented hemorrhage and malignant transformation in approximately 10% each, likely reflecting publication and severity bias. Discussion/Conclusion: This synthesis supports a pragmatic approach centered on a standardized operational definition, hepatobiliary-contrast MRI, selective targeted biopsy/molecular profiling of index lesions, withdrawal of exogenous hormones, and risk-adapted intervention for high-risk disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine Residency Program, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Georgetown University School of Medicine, Georgetown University, Washington, DC, USA.
- University of Pikeville-Kentucky College of Osteopathic Medicine, Pikeville, KY, USA.
- Internal Medicine Residency Program, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
- MedStar Georgetown University Hospital, Department of Transplant Hepatology, Washington, DC, USA.
ORCID-Profile: Thomas Stirrat
Zitieren
APA
Stirrat, T., Kim, S., Bejugam, D., Apte, S., Flatley, M., & Rangnekar, A. S. (2026). Hepatic Adenomatosis: A Systematic Review of Definitions, Management, and Outcomes in Published Cases. GE - Portuguese Journal of Gastroenterology, 33(1), 606-619. https://doi.org/10.1159/pjg/acwag002
Vancouver
Stirrat T, Kim S, Bejugam D, Apte S, Flatley M, Rangnekar AS. Hepatic Adenomatosis: A Systematic Review of Definitions, Management, and Outcomes in Published Cases. GE - Portuguese Journal of Gastroenterology. 2026;33(1):606-619. doi:10.1159/pjg/acwag002
BibTeX
@article{Stirrat2026,
author = {Stirrat, Thomas and Kim, Stella and Bejugam, Deeptha and Apte, Soham and Flatley, Michael and Rangnekar, Amol S},
title = {Hepatic Adenomatosis: A Systematic Review of Definitions, Management, and Outcomes in Published Cases},
journal = {GE - Portuguese Journal of Gastroenterology},
year = {2026},
volume = {33},
number = {1},
pages = {606--619},
doi = {10.1159/pjg/acwag002}
}
EUVIMED